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GF signaling uses receptor tyrosine kinases that form
high-afﬁnity complexes with FGFs and heparan sulfate
 
(HS) proteoglycans at the cell surface. It is hypothesized
that assembly of these complexes requires simultaneous
recognition of distinct sulfation patterns within the HS
chain by FGF and the FGF receptor (FR), suggesting that
tissue-speciﬁc HS synthesis may regulate FGF signaling. To
address this, FGF-2 and FGF-4, and extracellular domain
constructs of FR1-IIIc (FR1c) and FR2-IIIc (FR2c), were used
to probe for tissue-speciﬁc HS in embryonic day 18 mouse
embryos. Whereas FGF-2 binds HS ubiquitously, FGF-4
exhibits a restricted pattern, failing to bind HS in the heart
F
 
and blood vessels and failing to activate signaling in mouse
aortic endothelial cells. This suggests that FGF-4 seeks a
speciﬁc HS sulfation pattern, distinct from that of FGF-2,
which is not expressed in most vascular tissues. Addition-
ally, whereas FR2c binds all FGF-4–HS complexes, FR1c
fails to bind FGF-4–HS in most tissues, as well as in Raji-S1
cells expressing syndecan-1. Proliferation assays using
BaF3 cells expressing either FR1c or FR2c support these
results. This suggests that FGF and FR recognition of speciﬁc
HS sulfation patterns is critical for the activation of FGF
signaling, and that synthesis of these patterns is regulated
during embryonic development.
 
Introduction
 
Heparan sulfate (HS)* is prevalent at the cell surface and in
the extracellular matrix of developing organs. Its cell surface
distribution is attributed to membrane-intercalated pro-
teoglycans that include the syndecans (Zimmermann and
 
David, 1999), glypicans (Filmus, 2001), CD44(V3) (Ben-
nett et al., 1995; Jackson et al., 1995), and betaglycan
(Andres et al., 1989). HS in the matrix is expressed largely
 
on perlecan in basement membranes and the interstitial
matrix (Noonan et al., 1991; Iozzo, 1998). HS proteogly-
cans have diverse functions, ranging from cell adhesion to
growth factor signaling, with roles for both the core proteins
and HS glycosaminoglycan chains (Bernfield et al., 1999;
Park et al., 2000). The most prevalent interactions are via
the HS chains for which ligands include matrix components
(i.e., collagens, fibronectin, laminins, etc.), growth factors
(i.e., FGFs, the EGF family, PDGF-L, hepatocyte growth
factor, vascular endothelial growth factor, etc.), matrix me-
talloproteinases, lipoproteins and lipases, and viruses (Bern-
field et al., 1999).
Binding of growth factors to HS has several potential
functions. One established function for FGFs is protection
of the growth factors from endogenous proteases (Gospo-
darowicz and Cheng, 1986). A second is retention of the
growth factors at sites of function by the extracellular matrix
(Flaumenhaft et al., 1990). Indeed, HS may limit their dif-
fusion and maintain them in active or inactive states, thus
generating sites of local activity and morphogenetic bound-
aries, roles that have been confirmed by emerging genetic
studies (Lin et al., 1999; The et al., 1999; Tsuda et al.,
1999). Regulation of active or inactive states depends on a
third HS function: direct participation of the HS in assem-
bly of the cell surface signaling apparatus. This was first
identified in cells deprived of endogenous HS, which cur-
tails FGF binding to its receptor tyrosine kinase (FR) and re-
ceptor signaling (Rapraeger et al., 1991; Yayon et al., 1991).
This finding has been refined for several members of the
FGF family as well as other growth factors, among them
hepatocyte growth factor (Sakata et al., 1997; Sergeant et al.,
2000), heparan-binding EGF (Kleeff et al., 1998; Paria et
al., 1999), and vascular endothelial growth factor (Cohen et
al., 1995; Gengrinovitch et al., 1999).
23 members of the FGF family have been identified and
each retains an identifiable, although varying, HS-binding
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domain (Faham et al., 1998; Rapraeger, 2001). These pro-
teins signal through a four-member family of receptor ty-
rosine kinases (Johnson and Williams, 1993; Szebenyi and
Fallon, 1999). The ectodomain of the FR contains three Ig-
like domains (D1–D3), in which D2 and D3 mediate FGF
binding. The interaction of FGF and D3 is a direct protein–
protein interaction using the membrane-proximal half of
D3. This region is also subject to splicing variation, which
influences FGF binding specificity (Miki et al., 1992;
Werner et al., 1992; Ornitz et al., 1996). FGF binding to
the D2 region also includes a direct interaction that can vary
with FGF type (Chellaiah et al., 1999), and a second inter-
action that is mediated by a single HS chain that binds both
proteins and stabilizes their association. This utilizes HS
binding domains that are present in the FGF and within D2
of the FR (Kan et al., 1993). Multiple models for the FR–
FGF–HS interaction have been proposed, attempting to ex-
plain how HS promotes binding, oligomerization, and sig-
naling by this monomeric growth factor (Venkataraman et
al., 1999; Pellegrini et al., 2000; Schlessinger et al., 2000).
In each proposed model, a central question is whether the
pattern of sulfation within the HS chain serves to stabilize
different FGF and FR pairs, thus regulating the signaling by
these growth factors.
It is postulated that HS is encoded with binding specific-
ity by a highly regulated mechanism of synthesis involving
sugar epimerization and variable sulfation (Lindahl, 1997;
 
Lindahl et al., 1998; Guimond and Turnbull, 1999). Syn-
thesis of the HS backbone of alternating glucuronate and
 
N
 
-acetylglucosamine residues is followed by the action of other
enzymes that epimerize and variably modify regions within
the chain by sulfation of specific residues (Wei et al., 1993;
Kobayashi et al., 1997; Li et al., 1997; Shworak et al., 1997;
Habuchi et al., 1998; Lindahl et al., 1998) (Fig. 1 A). Al-
though the number of sites on a single sugar residue that can
be sulfated is relatively few, the potential variation within a
span of many saccharides increases geometrically with each
subsequent disaccharide added, and leads to the formation
of discrete domains within the HS chain. In fact, in vitro ex-
periments with a library of HS saccharides generated by en-
zymatic or chemical cleavage has demonstrated that FGF
binding to HS and signaling depends upon such block se-
quences of variable sulfation that arise during synthesis of
the glycosaminoglycan chain (Turnbull et al., 1992; Gui-
mond et al., 1993; Pye et al., 1998) (Fig. 1 B). However, an
important question is whether specific HS binding struc-
tures are expressed in a distinct pattern in vivo. If specific
binding domains are indeed present within different tissues,
the next question is whether they are selectively recognized
by specific FGFs, and whether the recognition of these
FGF–HS complexes by individual FRs is also determined by
the HS to which the FGF is bound.
To directly look for tissue-specific HS expression patterns
that may regulate growth factor activity, we have used FGF-2
Figure 1. Regulated biosynthesis of 
heparan sulfate. (A) HS copolymerases 
(EXT) synthesize the glycosaminoglycan 
chain on a linkage tetrasaccharide 
attached to serine of the proteoglycan core 
protein. The chain is then modified by a 
series of concerted enzymatic reactions. 
The first enzyme to act is an N-deacety-
lase/N-sulfotransferase. This enzyme 
modifies selected sites throughout the 
chain, although it is unclear how these 
sites are selected. Regions of the chain that 
undergo N-deacetylation and sulfation of 
the glucosamine are then targets for further 
variable modification as shown (modified 
from Lindahl, 1997) and are interspersed 
with unmodified regions. The further 
modifications include epimerization of 
glucuonate to iduronate, 2-O-sulfation of 
the uronic acid or sulfation of the 
glucosamine in the 6 position. The last 
family of enzymes to act on the chain are 
the 3-O-sulfotransferases, which act on 
different sites within the chain depending 
on which prior modifications have taken 
place. (B) A postulated HS fragment neces-
sary for FGF-2 binding and activity. The 
length of the fragment necessary for FGF-2 
binding is a hexasaccharide that contains 
2-O-sulfation of iduronic acid. The length 
of the fragment necessary for FGF-2 
activity is a dodecasaccharide that bears 
6-O-sulfation of the glucosamine residues. 
Note that the actual position of the resi-
dues within this sequence is not known. 
Ac, acetyl; circled and shaded S, SO3. 
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and FGF-4 as probes to detect HS in frozen sections of the de-
veloping mouse embryo. In addition, the ability of tissue-spe-
cific HS to assimilate these FGFs into a complex with an FR
was tested with two soluble FR constructs. FGF-2 and FGF-4
were chosen because they reportedly bind to the same signal-
ing receptors, act on a wide variety of cell types, and have sim-
ilar mitogenic activities using reporter cells (Ornitz et al.,
1996; Szebenyi and Fallon, 1999). The two soluble receptor
probes were FGF receptor 1-IIIc variant (FR1c) and FGF re-
ceptor 2-IIIc variant (FR2c), consisting of the ectodomains of
these FRs expressed as fusion proteins with human placental
alkaline phosphatase (AP). These receptor isoforms recognize
both FGF-2 and FGF-4 when bound to heparin, a highly sul-
fated form of HS. The results of using these probes on endog-
enous HS in the embryonic day 18 (E18) mouse demonstrate
that although FGF-2 and FGF-4 bind to HS in many of the
same tissues, FGF-4 does not recognize HS in the heart and
major blood vessels, suggesting that (a) FGF-2 and FGF-4
recognize different HS chains, or different sulfation patterns
within the same HS chain, and (b) the sulfation pattern recog-
nized by FGF-4 is not expressed in most vascular tissues. Sec-
ond, although FR1c and FR2c bind FGF-2 and FGF-4
equally in the presence of heparin, endogenous HS supports
the binding of FGF4 to FR1c only in rare cases, whereas HS
supports the binding of FGF-4 to FR2c in all sites examined.
This demonstrates not only that HS is expressed in a cell- and
tissue-specific manner, but that the specific synthesis of HS
may be a critical regulator of HS-binding growth factors.
 
Results
 
FGF-2 and FGF-4 bind HS in E18 mouse skin
 
FGF-2 and FGF-4, like all members of the FGF family,
bind heparin. In addition, when bound by heparin, both
FGFs activate FR1c and FR2c. However, because HS has a
more variable sulfation pattern than heparin, it is not clear
that HS expressed by all cell types would promote these
interactions. To examine the possibility that HS is synthe-
sized with a tissue-specific structure, exogenous FGF-2 and
FGF-4 were used as probes for specific HS in tissue sections
from E18 mouse embryos. Total HS was mapped with
mAb3G10, which recognizes the residual HS stub on en-
dogenous core proteins after digestion with heparitin-
ase. Antibody staining demonstrates that HS is prevalent
throughout the epidermis and dermis of E18 mouse skin,
exhibiting prominent staining in the epithelial basement
membrane, in skeletal muscle, and in cartilage of the devel-
oping rib (Fig. 2 A). FGF-2 staining mirrors that of HS,
suggesting that it binds HS ubiquitously (Fig. 2 B). Binding
is seen at cell surfaces and also in basement membranes, as
well as elsewhere in the matrix. Importantly, binding to the
tissue sections is completely blocked by HS degrading en-
zymes (Fig. 2 C), suggesting that the binding of FGF-2 is
completely HS dependent. Detection of FGF-4 in the skin
yields similar results. FGF-4 binds ubiquitously to HS (Fig.
2 D) and, like FGF-2, fails to bind following pretreatment
with heparitinase (unpublished data).
 
FGF-4 fails to bind HS in E18 mouse heart
 
Despite the similarities in FGF-2 and FGF-4 recognition of
HS in the mouse skin, other sites in the mouse display strik-
ingly different binding patterns. One example is HS in the
E18 mouse heart. Staining with mAb3G10 identifies HS
throughout the atrium and ventricle of the heart, as well as
in neighboring lung tissue (Fig. 3 A). As seen in the skin, the
FGF-2 binding pattern is identical to that of the HS distri-
bution (Fig. 3 B), and is completely dependent on HS (Fig.
3 C). However, FGF-4, which binds strongly to HS in the
Figure 2.  FGF-2 and FGF-4 bind specifically 
to endogenous HS in E18 mouse skin. The area 
shown is a section of skin in an E18 stage mouse 
embryo. (A) Total HS distribution is detected by 
mAb3G10 following treatment of the section 
with the heparin lyase I and heparin lyase III 
(heparitinase treatment). (B) Exogenous FGF-2 
binding is detected with Ab DE6 after incubation 
with 30nM FGF-2. (C) FGF-2 binding following 
pretreatment with heparitinase. (D) Exogenous 
FGF-4 binding is detected with Ab AF235 after 
incubation with 30 nM FGF-4. BM, basement 
membrane; Ca, cartilage; SkM, skeletal muscle. 
Bar, 100  m. 
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lung, fails to recognize HS in either the atrium or the ventri-
cle of the heart (Fig. 3 D).
Examination of the lung provides further insight into the
FGF binding specificity. In the lung, mAb3G10 identifies
HS that is prevalent not only within lung tissue, but also
within blood vessels (Fig. 4 A). A major blood vessel is identi-
fied by smooth muscle actin staining. Although FGF-2 binds
HS in both lung tissue and the vessel, FGF-4 binds HS in the
lung tissue, but fails to bind the blood vessel HS. This sug-
gests that endothelial and smooth muscle cells lining the ves-
sel express HS that contains a specific sulfation pattern that is
recognized by FGF-2, but not by FGF-4. This was tested di-
rectly by examination of the binding of either FGF-2 or
FGF-4 to HS on cultured mouse aortic endothelial cells.
Whereas FGF-2 binds HS on the endothelial cells, FGF-4
binding is negative. To confirm that the apparent failure of
FGF-4 to bind to HS on mouse aortic endothelial cells
(MAECs) correlates to a lack of activity, cells were treated
with either FGF-2 or FGF-4 in the absence or presence of
heparin (Fig. 4 B). Importantly, MAECs have been shown to
express FR2c, an FR isoform that is thought to be equally ac-
tivated by FGF-2 and FGF-4 (Ornitz et al., 1996; Bastaki et
al., 1997). In the absence of any treatment, MAECs adopt a
highly spread morphology. Treatment with FGF-2 stimulates
these cells to drastically change their morphology, adopting a
spindle-like, polar morphology and likely reflects FGF-
induced motility. In contrast, FGF-4 treatment stimulates no
morphology change in these cells. However, treatment with
Figure 3.  FGF-2 and FGF-4 binding to HS in the 
E18 mouse heart and lung. A section of the atrium 
and ventricle of the E18 mouse heart, as well as 
neighboring lung tissue is shown. Treatment and 
detection are as described in Fig. 2. (A)Total HS 
detected with mAb 3G10; (B) binding of FGF-2; (C) 
binding of FGF-2 following heparitinase treatment; 
(D) binding of FGF-4. Dashed lines represent the 
borders of the atrium and ventricle, which do not 
stain in (D). At, atrium; Ve, ventricle; Lu, lung. 
Bar, 100  m.
 
Table I. 
 
FGF and FR recognition of tissue-specific HS in E18 mouse embryos
Probe
FGF-2 
 
 
 
FGF-4 
 
 
 
HS site FGF-2 FR1cAP FR2cAP FGF-4 FR1cAP FR2cAP
 
Skin
 
      
 
Skeletal muscle
 
      
 
Mast cells
 
      
 
Gut
 
      
 
Rib
 
      
 
Kidney
 
      
 
Lung
 
      
 
Liver
 
      
 
Submandibular gland
 
      
 
Adrenal gland
 
      
 
Atrium
 
      
 
Ventricle
 
      
 
Artery
 
      
 
Vein
 
      
 
Brain capillary
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heparin, which has no effect alone, causes MAECs to adopt
this spindle-like morphology in the presence of either FGF-2
or FGF-4. These data are consistent with previously pub-
lished results regarding the response of endothelial cells to
FGF-2 and FGF-4 (Delli-Bovi et al., 1988; Dell’Era et al.,
2001), and suggest that the fine structure of HS on these cells
regulates their response to different FGF family members.
Although FGF-4 fails to recognize HS in both the heart
and large blood vessels, there is vascular HS that is recognized
by FGF-4. In E16 mouse embryos, mAb3G10 staining con-
firms the presence of HS in capillaries and the choroid plexus
within the brain (Fig. 5
 
 
 
A). The capillaries are identified by
staining for platelet–endothelial cell adhesion molecule (PE-
CAM)1 (unpublished data). FGF-2 binds HS in the capillar-
ies and in the choroid plexus (Fig. 5 B). FGF-4 fails to bind
HS in the choroid plexus, similar to the difference seen be-
tween FGF-2 and FGF-4 binding in the heart. However,
FGF-4 does recognize the HS in the brain capillaries with ap-
parently equal intensity as the FGF-2 binding (Fig. 5
 
 
 
D).
The binding of FGF-2 and FGF-4 to major HS sites in
the E18 mouse embryo is summarized in Table I. FGF-2
binds to HS in all sites examined, suggesting that the sulfa-
tion pattern necessary for its binding is ubiquitous. Inter-
estingly, FGF-4 binds HS in many of the same organs as
FGF-2, including lung, liver, and kidney. FGF-4 also binds
HS in glandular structures, such as the adrenal gland as well
as the submandibular gland. As described above, the most
striking results are in the vascular system, where FGF-4 fails
to bind HS in both the heart and in large blood vessels, al-
though it does recognize HS in brain capillaries.
 
FR1cAP and FR2cAP bind equally to FGF-2 and FGF-4 
immobilized on heparin
 
Regulation of FGF signaling by HS is dependent not only
on FGF binding to sites within the HS chain, but also on si-
multaneous FR recognition of the HS. The specificity re-
quired for receptor recognition is largely unknown, although
it has been shown that a library of HS decasaccharides can
differentially activate FGF signaling in cells engineered to
express specific FRs (Guimond and Turnbull, 1999). It is
possible that the HS specificity required for FGF binding is
also satisfactory for receptor binding, particularly if the
binding is stabilized by FGF–FR interactions. Alternatively,
receptor binding may be highly dependent on specific sulfa-
Figure 4.  FGF-2 and FGF-4 binding to endothe-
lial HS and signaling in cultured endothelial cells. 
(A) A region of the E18 mouse lung containing a 
large blood vessel is shown, with FGF treatments 
as described in Fig. 2. Top panels (from left to 
right): mAb 3G10 detection of total HS; binding of 
FGF-2 to tissue; FGF-2 binding to cultured mouse 
aortic endothelial cells (MAECs). Bottom panels 
(from left to right): staining for smooth muscle 
actin; binding of FGF-4; FGF-4 binding to MAECs. 
Dashed circle denotes the border of a large artery 
within the lung, to which FGF-4 fails to bind. (B) 
Assessment of MAEC morphology after FGF 
treatment. Top panels (from left to right): no 
treatment; 10 nM FGF-2; 10 nM FGF-4. Bottom pan-
els (from left to right): 10 nM heparin; 10 nM
FGF-2   10 nM heparin; 10 nM FGF-4   10 nM
heparin. Bars: (A) Bottom middle panel, 100  m; 
Bottom right panel, 100  m; (B) Top right panel,
20  m. 
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tion patterns such that FGFs will only be recognized by the
receptor when bound to sites containing HS sequences that
are specific for both the FGF and the FR.
To test these possibilities, soluble extracellular ligand
binding domains of FR1c and FR2c fused to human placen-
tal alkaline phosphatase (FR1cAP and FR2cAP, respectively)
were used as probes to address receptor binding to the FGF–
HS complexes assembled on the tissue sections. Both FR1c
and FR2c are strongly activated by complexes of FGF-2–
heparin and FGF-4–heparin, and so are ideal receptors to
use as probes for the detection of tissue-specific HS. Both
FR1cAP and FR2cAP were expressed in COS-7 cells and
purified from COS-7–conditioned medium. Because each
FR contains an HS binding domain, receptor constructs
were subjected to 1-M NaCl washes during purification to
remove any endogenous HS that may have bound the FR.
Comparison of constructs purified with or without the 1-M
NaCl wash showed no difference in the ability of either
FRAP construct to bind to heparin or HS, suggesting that
either no endogenous HS copurified with the receptors, or
that a sufficiently low amount of HS copurified such that no
differences could be detected (unpublished data).
To confirm that the receptor constructs are functional, each
receptor was incubated with heparin agarose beads (HABs) in
the presence or absence of either FGF-2 or FGF-4. In the ab-
sence of FGF, FR1cAP fails to bind HABs (Fig. 6 A, white
bar), although FR2cAP does display some binding (Fig. 6 B,
white bar). The binding of FR2cAP to HABs is specific, as it
is competed with excess soluble heparin (Fig. 6 B, black bar).
Additionally, FR2cAP binding to heparin can also be dis-
rupted by washing the beads with 0.35 M NaCl (Fig. 6 B,
gray bar). In contrast, in the presence of either FGF-2 or
FGF-4, FR1cAP and FR2cAP bind strongly (Fig. 6, A and B,
vertical and horizontal lined bars), and this is not disrupted by
Figure 5.  FGF-4 binds capillary HS in the brain. 
Serial sections of E16 mouse brain, treated with 
FGFs as in Fig. 2. (A) Total HS localized by 
mAb3G10. (B) Binding of FGF-2. (C) Binding of 
FGF-2 after heparitinase treatment. (D) Binding of 
FGF-4. BV, blood vessels; CP, choroid plexus. 
Blood vessels are identified by staining with anti–
PECAM-1 Ab (unpublished data). Bar, 100  m.
 
Figure 6.
 
  FR1cAP and FR2cAP binding to FGF-2–heparin and 
FGF-4–heparin on agarose beads.
 
 Percent of FRAP bound to HABs: 
in the absence of FGF; after incubation with excess soluble heparin; 
after 0.35 M NaCl wash; after 0.35 M NaCl wash in the presence of 
FGF-2 or FGF-4; after incubation with excess soluble heparin in the 
presence of FGF-2 or FGF-4. (A) FR1cAP; (B) FR2cAP.  
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a 0.35-M NaCl wash. This is consistent with previously pub-
lished results (Ornitz et al., 1992). As with the binding of
FR2cAP alone, formation of a ternary complex of FGF–
HAB–FRAP is abrogated by incubation with excess soluble
heparin (Fig. 6,
 
 
 
A and B, cross-hatched and brick bars).
 
FR1cAP fails to recognize FGF-4–HS complexes in E18 
mouse skin
 
To determine whether FR1cAP and FR2cAP bind FGF-2
and FGF-4 equally when endogenous HS participates rather
than heparin, the soluble receptors were used to probe E18
mouse skin, where both FGF-2 and FGF-4 bind equally to
endogenous HS (compare Fig. 7 with Fig. 2). FR1cAP and
FR2cAP were incubated with tissue sections in either the ab-
sence or presence of FGF-2 or FGF-4. In the absence of
FGF, neither receptor binds to HS in E18 mouse skin tissue
sections (Fig. 7, A and B). In the presence of FGF-2, both
FR1cAP and FR2cAP bind FGF-2–HS in an identical pat-
tern that corresponds to the distribution of FGF-2 (Fig. 7, C
and D). Again, this binding is dependent on the presence of
FGF-2–HS complexes, as pretreatment with heparitinase
completely abrogates receptor binding (unpublished data).
Interestingly, in the presence of FGF-4, FR1cAP fails to
bind any FGF-4–HS complexes in the skin (Fig. 7 E),
whereas FR2cAP appears to bind all FGF-4–HS complexes
in the section (Fig. 7 F). As an important internal control,
FR1cAP does recognize FGF-4–heparin complexes as shown
by the bright punctate staining of mast cells, which contain
heparin in 
 
 
 
-granules (Fig. 7 E). This result suggests that
whereas FR1cAP does recognize FGF-4 in the context of
highly sulfated heparin, HS in the skin lacks the appropriate
sulfation sequence necessary for the recognition of FGF-4 by
FR1cAP. Additionally, these results suggest that HS in the
skin does contain the appropriate sulfation sequence neces-
sary for FR1cAP recognition of FGF-2 and FR2cAP recog-
nition of both FGF-2 and FGF-4.
 
FR1cAP recognizes FGF-4–HS in the E18 mouse liver 
and kidney
 
Whereas FR1cAP fails to recognize FGF-4 bound to HS in
the E18 mouse skin, there are specific sites where FR1cAP
does recognize FGF-4–HS complexes. One such site is in
the E18 mouse liver. In a section containing the lung, dia-
phragm, and liver, 3G10 staining identifies the presence of
HS at cell surfaces including lung epithelia, muscle of the di-
aphragm, and hepatocytes within the liver (Fig. 8 A). In ad-
dition, HS is prominent in the basement membrane of the
lung, and serosal lining of the liver, as well as the lining of
the liver sinusoids. Exogenous FGF-2 recognizes HS in all of
these tissues (Fig. 8 C). However, whereas FGF-4 binds HS
Figure 7.  FR1cAP and FR2cAP binding 
to FGF-2–HS complexes and FGF-4–HS 
complexes in E18 mouse skin. A region 
of mouse skin (top), dermis, and body 
wall is shown. The sections were 
incubated either with no FGF (A and B), 
30 nM FGF-2 (C and D), or 30 nM 
FGF-4 (E and F). After washing, the 
sections were incubated with 100 nM 
FR1cAP (A, C, and E) or 100 nM FR2cAP 
(B,D, and F). Bound FRAP is observed 
using anti-AP antibody. Ma, mast cells. 
Bar, 100  m.
Figure 8.  FR1cAP and FR2cAP binding 
to FGF–HS complexes in E18 mouse 
liver. A section of E18 mouse lung (Lu), 
diaphragm (Di) and liver (Li) is shown. 
Sections were incubated with 30 nM 
FGF-2 (B, C, E, and G) or 30 nM FGF-4 
(D, F, and H). After washing, sections 
were incubated with 100 nM FR1cAP (E 
and F) or 100 nM FR2cAP (G and H). 
Antibodies were used to detect total HS 
(A); FGF-2 binding after prior hepari-
tinase treatment (B); bound FGF-2 (C); 
bound FGF-4 (D); bound FR1cAP (E and 
F); and bound FR2cAP (G and H). Se, 
serosal lining of liver; Si, lining of liver 
sinusoids. Bar, 100  m. 
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in the lung epithelium and diaphragm, it binds only weakly
to HS in the serosa of the liver, although it does bind
strongly to the lining of the liver sinusoids (Fig. 8 D). In
contrast, both FR1cAP and FR2cAP bind FGF-2–HS
throughout the lung, liver, and diaphragm (Fig. 8, E and G).
Although FR1cAP appears to recognize FGF-2 in the dia-
phragm more avidly than FGF-2 bound to HS in the lung,
this is not a consistent result and is likely a source of experi-
mental variation. FR2cAP also binds FGF-4–HS in the
lung, diaphragm, and liver (Fig. 8 H), preferentially binding
to FGF-4–HS complexes in the lung rather than the dia-
phragm. However, FR1cAP fails to bind FGF-4–HS in ei-
ther the lung or in the diaphragm (Fig. 8 F). Nonetheless,
FR1cAP is able to recognize FGF-4–HS in the lining of the
liver sinusoids. Although this binding is not as strong as that
seen with FR1cAP binding to FGF-2–HS, it does suggest
that there is a subset of HS in the liver that promotes FGF-4
binding to FR1cAP.
A second site where FR1cAP recognizes FGF-4 bound to
endogenous HS is in the E18 mouse kidney. HS is identified
throughout the kidney, including prominent staining in
both the glomeruli and renal tubules (Fig. 9 A, insets). Both
FGF-2 and -4 bind HS strongly in the kidney (Fig. 9, C and
D), binding that is abolished by prior heparitinase treatment
(shown for FGF-2 in Fig. 9 B). FR1cAP recognizes FGF-2–
HS throughout the kidney (Fig. 9 E), as does FR2cAP (Fig.
9 G). FR2cAP also recognizes FGF-4–HS in the kidney, in-
cluding strong staining in both the glomeruli and renal tu-
bules (Fig. 9H). Hhowever, FR1cAP fails to bind FGF-4–
HS in the glomeruli of the kidney, although it does recog-
nize FGF-4–HS in the renal tubules (Fig. 9 F). This suggests
that there are multiple HS sequences present in different
structures within the kidney, and that a specific HS sulfation
sequence is present in renal tubules, but lacking in glomer-
uli, that is necessary for FR1cAP recognition of FGF-4.
FR1cAP and FR2cAP recognition of FGF-2 and FGF-4
when bound to endogenous HS is summarized in Table I.
FR1cAP binds FGF-2–HS throughout the E18 embryo. In
contrast, FR1cAP fails to recognize the majority of FGF-4–
HS complexes. The two major exceptions to this are the rec-
ognition of FGF-4–HS in the lining of the sinusoids of the
liver and within renal tubules of the kidney. These results,
when taken into consideration with the ability of FR1cAP to
recognize FGF-4–heparin in mast cells, suggest that a spe-
cific and rare HS sulfation sequence is necessary for FR1c
recognition of FGF-4.
 
HS regulation of FR1c and FR2c signaling
 
To confirm that the binding of soluble FRAPs to FGF–HS
complexes on the frozen tissue sections recapitulates the
mechanism by which an active FGF–HS–FGFR signaling
complex is assembled, cell proliferation assays were per-
formed with BaF3 cells expressing either FR1c or FR2c
(FR1c11 and FR2c2 cells, respectively). The parental BaF3
cells are a lymphoid cell line that is negative for both HS and
FGF receptor expression. These cells normally require inter-
leukin (IL)3 for survival; however, cells expressing FR con-
structs overcome this requirement and survive and prolifer-
ate when grown in the presence of the appropriate FGF
together with heparin. Both FR1c11 cells and FR2c2 cells
have been previously shown to proliferate equally in re-
sponse to treatment with either FGF-2 or FGF-4 in the
presence of heparin (Ornitz et al., 1996). The response to
FGF-4, either in the presence or absence of heparin is also
demonstrated here, indicating that this FGF activates either
FR1c or FR2c in the presence of this glycosaminoglycan
(Fig. 10, B and C).
To provide a source of HS that has the characteristics of
the majority of endogenous HS, which promotes binding of
FR1cAP to FGF-2 but not to FGF-4, the binding of these
FGFs and FRAPs were tested on Raji-S1 cells, a human lym-
phoblastoid cell line that has been transfected with the
cDNA for mouse syndecan-1 (Lebakken and Rapraeger,
1996). Indeed, the HS expressed on the syndecan-1 of these
cells contains a sulfation pattern similar to that seen in the
majority of the mouse embryo, namely, binding FGF-2 and
FGF-4 and promoting binding of FR2c AP to both growth
factors, and promoting binding of FR1c AP to FGF-2 but
not FGF-4 (Fig. 10 A).
To test the ability of these receptors to be activated by the
FGF–HS complexes on the Raji-S1 cells, the BaF3 cells ex-
pressing either FR1c or FR2c were cultured with FGF-2 or
FGF-4 on fixed monolayers of Raji-S1 cells. Similar to our
prior published work (Filla et al., 1998), the FR1c11 cells
cultured on fixed monolayers of Raji-S1 cells in the presence
of FGF-2 utilize the HS on the Raji cells to bind and re-
spond to the FGF (Fig. 10 B). In contrast, FR1c11 cells do
not respond to FGF-4 when grown on a fixed monolayer of
Figure 9.  FR1cAP binds FGF-4–HS in 
renal tubules of E18 mouse kidney. A 
section of E18 mouse kidney is shown. 
Higher magnification views of a glomer-
ulus (lower inset) and a renal tubule 
(upper inset) are also shown. Sections 
are incubated with 30 nM FGF-2 (B, C, 
E, and G) or 30 nM FGF-4 (D, F, and H). 
Following washing, sections were 
incubated with 100 nM FR1cAP (E and F) 
or 100 nM FR2cAP (G and H). Total HS 
(A), FGF-2 binding following heparitinase 
treatment (B), FGF-2 (C), FGF-4 (D) 
FR1cAP (E and F) and FR2cAP (G and H) 
are visualized by immunostaining. 
Bars: (H) 100  m; (inset) 100  m. 
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Raji-S1 cells, confirming the failure of FR1c to recognize
FGF-4 bound to this HS. FR2c2 cells also confirm the re-
sults seen using the FGFs and FRAP receptor probes in situ
(Fig. 10 C). In contrast to the FR1c11 cells, the FR2c2 cells
respond to both FGF-2 and FGF-4 when grown on a fixed
monolayer of the Raji-S1 cells shown to express HS that
promotes binding of FGF-4 to FR2c.
 
Discussion
 
A central question in the field of proteoglycan biology has
been whether the complex sequence of modifications that
occur during glycosaminoglycan synthesis serves a func-
tional role in vivo, particularly in the tissue specific regula-
tion of growth factor signaling. The integral role of heparan
sulfate as a component of the FGF signaling complex, where
it assembles with the FGF and the FR, suggests that the gen-
eration of specific sulfation patterns within the chain by spe-
cific cell types may regulate assembly of FGF family mem-
bers with their receptors. To address the question of whether
tissue-specific HS regulates FGF binding, exogenous FGF-2
and FGF-4 were used to probe and identify FGF-specific
HS in the developing mouse embryo. Although both FGF-2
and FGF-4 recognize heparin in vitro (and in mast cells in
vivo
 
)
 
, distinct differences exist in the ability of FGF-2 versus
FGF-4 to bind HS in vivo. In the E18 mouse, FGF-2 recog-
nizes HS in a ubiquitous manner, suggesting that essentially
all HS binds this growth factor. In contrast, whereas FGF-4
binds HS in many of the same sites as FGF-2, there are
other sites where FGF-4 fails to bind. A stark contrast is seen
in the vascular system where FGF-4 fails to bind to HS in
the heart and large blood vessels, as well as to aortic endothe-
lial cells in culture. Importantly, the failure of FGF-4 to
bind HS on these cells correlates with a failure of FGF-4 to
stimulate a response in these cells. However, a response can
be stimulated, when heparin is added, suggesting that the
correct FRs are indeed expressed on these cells, but that the
endogenous HS is inappropriate for FGF to bind and signal.
This result is surprising, as FGF-4, also known as k-FGF
(Delli-Bovi et al., 1988) or 
 
hst
 
 (Miyagawa et al., 1988), was
originally identified as an angiogenic factor with activity to-
ward endothelial cells. However, these studies typically
added heparin along with the FGF to achieve activity (Delli-
Bovi et al., 1988; Yoshida et al., 1994; Dell’Era et al., 2001).
Interestingly, FGF-4 binding to endothelial HS seems to
vary among blood vessels of different origin, as FGF-4 does
bind to HS in capillaries of the brain. A more detailed inves-
tigation will be necessary to determine whether this extends
to all capillaries, or whether this is a function of the tissue
type, as the phenotype of endothelial cells in various tissues
is clearly affected by the cadre of neighboring cells (Aird et
al., 1997).
It is also surprising that FGF-4 fails to bind in the heart
because of its role in early heart development. There is noth-
ing known about FGF-specific HS expression during heart
development, although it is clear that FGF induction of pre-
cardiac differentiation in vitro requires HS (Zhu et al.,
1996). Heart development from precardiac mesenchyme is
initiated before gastrulation by paracrine signaling originat-
ing in the endoderm and acting on the adjacent mesodermal
layer. This has been studied mostly in the chick embryo in
which the underlying endoderm at stage 5 expresses FGF-4,
along with FGF-1 and FGF-2. Any of these FGFs will in-
duce the proliferation and differentiation of cardiac myo-
cytes from the precardiac mesenchyme (Lough et al., 1996;
Zhu et al., 1996). These same FGFs reappear later during
heart chamber formation, where they are expressed in the
myocardium with autocrine roles in cardiomyocyte prolifer-
ation and differentiation (Zhu et al., 1996). Expression of
these FGFs in the heart is subsequently lost at later stages of
development. Interestingly, FGF expression in the chick is
largely paralleled by expression of FR1, which peaks at stage
Figure 10.  Regulation of binding and signaling of FR1c and FR2c 
by FGF bound to HS on Raji-S1 cells. (A) Fixed Raji-S1 cells are 
incubated with either with no FGF, 30 nM FGF-2 or 30 nM FGF-4, 
followed by 100 nM FR1cAP or FR2cAP. Bound receptor is detected 
with anti-AP antibody. (B) BaF3 cells expressing FR1c (FR1c11 cells) 
are either incubated in culture medium with no treatment, or 
incubated in medium with 10 nM heparin, 10 nM FGF-2 or FGF-4, 
or 10 nM FGF-2 or FGF-4   heparin. Alternatively, the FR1c11 cells 
are cultured on a fixed monolayer of Raji-S1 cells in the presence of 
10 nM FGF-2 or 10 nM FGF-4. After 3 d, relative cell number is 
assessed (A490). (C) BaF3 cells expressing FR2c (FR2c2 cells) are 
treated as in B. Bar, 200  m. 
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24, the stage when heart chamber formation is completed,
but persists until day 7 (Sugi et al., 1995). Expression then
declines in the ventricle but persists in the atrium. Impor-
tantly, these stages of FGF-4 expression in the chick com-
pare with E9–E11 in the mouse, which precede the mouse
E18 stage examined here. Because FGF-4 fails to bind the
heart HS and FR1c recognizes it only rarely when bound
elsewhere in the E18 embryo, it suggests that the HS struc-
ture may change with development. This is indeed suggested
by our preliminary data (unpublished data).
These results suggest that specific differences exist in HS
of both the heart and large blood vessels such that FGF-2,
but not FGF-4, is recognized. The ability of FGF-2 to bind
to most, if not all HS, indicates either that the FGF-2 bind-
ing motif in HS is a common HS sequence that is present in
all tissues, or that FGF-2 is able to recognize multiple HS
sulfation patterns, such that binding is not dramatically af-
fected by variations in HS structure. Where examined in de-
tail using isolated heparin or HS fragments, it has been
shown that FGF-2 binding is dependent on the minimum
of a pentasaccharide containing 2-
 
O
 
-sulfation (Turnbull et
al., 1992; Guimond et al., 1993; Maccarana et al., 1993)
(Fig. 1 B). Thus, the presence of 2-
 
O
 
-sulfation may be suffi-
cient for FGF-2 binding, regardless of what other sulfate
groups are present.
The failure of FGF-4 to bind in the vascular tissue sug-
gests that the binding motif for FGF-4 is different from that
of FGF-2, and that this motif is lacking in the heart and ma-
jor blood vessels. Although there are fewer data regarding
the HS binding requirements of FGF-4 than FGF-2, previ-
ous studies have suggested that binding of this growth factor
is dependent on HS containing a high content of 
 
N
 
-sulfo-
glucosamine–bearing 6-
 
O
 
-sulfate groups (Guimond et al.,
1993). This supports the findings here that FGF-2 and
FGF-4 recognize different sites; however, these prior experi-
ments, which are aimed primarily at specific types of sul-
fation (i.e., 2-
 
O
 
-sulfation, or 6-
 
O
 
-sulfation) rather than
specific motifs within the HS chain, provide insufficient in-
formation on what the specific motifs might be.
Overall, these results suggest that the HS in the walls of
vascular elements has very different FGF binding capabili-
ties, which may have far-reaching implications during vascu-
lar development and tumor-mediated angiogenesis, where
FGFs are known to play an important role (Slavin, 1995;
Beckner, 1999). Additionally, the finding that tissue-specific
HS regulates FGF binding is likely to have a major impact
not only on the 23 FGFs, but also on other HS-binding
growth factors, including BMPs, wnts, and hedgehogs,
among others (Bernfield et al., 1999).
The ability of FGFs to bind tissue-specific HS fulfills only
part of the requirement necessary for activation of FGF signal-
ing, however, as FRs must also recognize specific HS structures
in order to bind to and be activated by a particular FGF. Previ-
ous studies have shown that FGF-2 activity via FR1c requires a
dodecasaccharide (twice the length necessary for binding
alone) bearing glucosaminyl-6-
 
O
 
-sulfates in addition to the
iduronysyl-2-
 
O
 
-sulfates necessary for FGF-2 binding (Gui-
mond et al., 1993; Pye et al., 1998; Turnbull et al., 1992)
(Fig. 1 B). This additional length and sulfation requirement
represents a second level of HS specificity that is likely to be
important for assembly with FRs leading to signaling. Indeed,
heparin depleted of 6-
 
O
 
-sulfates will bind FGF-2 essentially as
well as native heparin or HS, but will inhibit the growth factor
by failing to assemble with the FR (Guimond et al., 1993).
Importantly, recent evidence suggests that it is not merely the
presence of 6-
 
O
 
-sulfates that is critical for signaling, but also
the location of the 6-
 
O
 
-sulfates on the HS chain that plays a
critical role in FR activation (Guimond and Turnbull, 1999).
In the current study, FR1c recognizes FGF-2–HS com-
plexes throughout the E18 mouse embryo; this recognition
is duplicated by FR2c. Given these data alone, it would be
tempting to conclude that HS serves as nothing more than a
nonspecific partner for the FGF and receptor. However,
When taken in the context of the inability of FR1c to recog-
nize FGF-4–HS in the vast majority of sites within the em-
bryo, a different story emerges. The fact that FR1c recog-
nizes FGF-4–heparin both in vitro and in vivo, but fails to
recognize FGF-4–HS at most sites suggests that FRs do in-
deed require specific HS sulfation sequences in order to rec-
ognize a specific FGF. Additionally, the data suggest that the
HS sequence necessary for FGF recognition differs between
FRs, as FR2c does recognize FGF-4–HS throughout the em-
bryo. Indeed, one wonders if FR2c and FR1c are binding ex-
actly the same sites even when they bind to the FGF-2–HS
complexes. It is entirely possible that these are actually dis-
tinct HS chains, or at least distinct sites on HS chains.
Previous studies provide at least partial explanations for
the two tissues, namely the liver and the kidney, where FR1c
does recognize FGF-4. In the liver, the structure of HS has
been characterized as being highly sulfated, and in fact, hep-
arin-like (Lyon et al., 1994). As a result, it is likely that the
rare sulfation sequence necessary for FR1c recognition of
FGF-4, which exists in heparin, also exists on the heparin-
like HS chains present in this site. In the kidney, it has been
shown that the HS is heterogeneous, with the detection of at
least five different HS species by antibodies generated via
phage display (van Kuppevelt et al., 1998). The presence of
an HS sequence in the kidney that promotes FR1c–FGF-4
complex formation, when combined with the knowledge
that both FGF-4 and FR1c are expressed simultaneously in
the developing kidney (Cancilla et al., 1999), supports the
notion that HS has a regulatory role in FGF-4 signaling dur-
ing kidney development. The fact that mice that lack the en-
zyme necessary for 2-
 
O
 
-sulfation of HS fail to develop func-
tional kidneys may also implicate the HS in binding either
FGFs or FRs (Bullock et al., 1998).
The lack of binding specificity in the case of FR1c recog-
nition of FGF-2 or FR2c recognition of either FGF-2 or
FGF-4 suggests several possibilities. In the case of FGF-2, it is
likely that the minimum HS requirements necessary for re-
ceptor recognition are common components of HS biosyn-
thesis. This is an intuitive result, as FGF-2 is one of the most
widely expressed FGF family members and likely serves to
signal in a wide variety of tissues and under a wide variety of
physiological and pathological conditions (Baird, 1994; Sze-
benyi and Fallon, 1999). In this case, HS may serve as a facil-
itator of FGF-2 signaling rather than as a regulator. However,
in the case of FGF-4, HS appears to be serving a regulatory
role. It is clear that HS allows recognition of FGF-4 by FR1c
in only very specific sites in the E18 stage embryo, whereas 
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FR2c recognizes FGF-4–HS on a much broader level. In
each of these cases, it will be of interest to examine both FGF
and receptor binding at earlier stages of development and in
tissues where the FGFs and FRs are expressed and known to
play a role, such as limb development in the case of FGF-4
(Martin, 1998). Further studies using other potential FGF
receptors (including splice variants) as well as other FGF fam-
ily members should identify additional specificity of these HS
moieties in the regulation of FGF signaling.
Although it is widely accepted that HS is required for the
formation of a high affinity FGF–FR signaling complex,
there are few in vivo data regarding the ability of specific HS
structures to regulate complex formation. The method used
here provides a highly useful approach for mapping differ-
ences in HS structure and relating them directly to FGF ac-
tivity. Although it is difficult to be certain that the binding of
exogenous FGFs to the tissue sections is dependent only on
the HS and is not influenced also by endogenous FRs, this
seems unlikely as the FGFs bind to sites in the matrix where
FRs are not expressed. In addition, we have shown that the
putative FGF–HS complexes that are formed can be recog-
nized by the exogenous FR probes. Furthermore, the predic-
tions derived from the use of these FGF and FR probes are
verified by activity studies using the BaF3 cells expressing
FR1c or FR2c. Thus, it seems apparent that tissue-specific
HS differentially regulates the binding of FGF-2 and FGF-4
in the developing mouse and also regulates the recognition of
these FGFs by FR1c and FR2c in a tissue-specific manner.
These results suggest a new paradigm where the formation of
specific FGF–FR signaling complexes is regulated not only
by the presence of HS, but also by site specific expression of
distinct HS sequences necessary for complex formation.
 
Materials and methods
 
Preparation of FGF receptor–alkaline phosphatase
fusion proteins
 
Soluble FGF receptor–alkaline phosphatase (FRAP) fusion proteins consist
of the extracellular three Ig-like loop domains of the IIIc splice variants of ei-
ther FR1 or FR2 fused to the NH
 
2
 
 terminus of human placental-AP (FR1cAP
and FR2cAP, respectively) (Ornitz et al., 1992). The FRAP cDNAs, provided
by Dr. David Ornitz (Washington University, St. Louis, MO), were cloned
into pcDNA3 and transfected into COS-7 cells using the calcium phosphate
method and selected in 600 
 
 
 
g/ml Geneticin (G418 sulfate; GIBCO BRL).
FRAP protein was purified from conditioned medium on an anti–human
placental AP-agarose column (Sigma-Aldrich) (Chang et al., 2000). FRAP
immobilized on the column was washed with PBS containing 1 M NaCl to
remove any endogenous HS that may have been bound to the receptor.
The amount of active FRAP protein was quantified by measuring the AP
activity of the samples using 
 
p
 
-nitrophenyl phosphate (Ornitz et al., 1992).
The activities of human placental AP standards (Sigma-Aldrich) of known
concentrations were used to estimate FRAP concentration.
 
In vitro heparan binding assays
 
Analysis of FRAP binding to FGF–heparin complexes was performed using
HABs (Bio-Rad Laboratories). FRAP was incubated in tissue culture media
(Hepes-buffered RPMI [HbRPMI] 
 
 
 
 10% CS 
 
 
 
 
 
L
 
-gln) at a concentration of
100 nM with 10 
 
 
 
l HABs in either the absence or the presence of 30 nM hu-
man recombinant FGF-2, provided by B. Olwin (University of Colorado,
Boulder, CO) or 30 nM human recombinant FGF-4 (R&D Systems) for 1 h at
room temperature on a rotator. The HABs bearing FRAP were washed three
times with either PBS or PBS containing 350 mM NaCl, resuspended in PBS,
and loaded into 96-well plates with an equal volume of AP substrate solution
and AP activity determined by absorbance at 405 nm. The amount of receptor
bound was calculated as a percent of the total amount of receptor added to
each treatment group.
 
In situ HS binding assays
 
Frozen tissue sections were incubated for FGF detection as described
(Friedl et al., 1997). Sections from E16 and E18 stage CD-1 mouse em-
bryos (Charles River Laboratories) were cut at a thickness of 5 
 
 
 
m, air
dried, and then fixed in 4% paraformaldehyde on ice. Two washes with
cold 0.05% NaBH
 
4
 
 followed by overnight treatment in PBS containing 0.1 M
glycine at 4
 
 
 
C served to reduce autofluoresence of the tissues. Sections
were blocked for 1 h at room temperature in TBS containing 10% fetal calf
serum (Hyclone). Incubation of sections with FGF was for 1 h with 30 nM
FGF-2 or 30 nM FGF-4. After three washes with TBS, bound FGF-2 was de-
tected with 1:500 DE6 anti–FGF-2 antibody (a gift of DuPont), or bound
FGF-4 was detected with 1:100 AF235 anti–FGF-4 antibody (R&D Sys-
tems) and Alexa-conjugated secondary antibodies (Molecular Probes).
Treatment of sections with 0.006 IU/ml heparin lyase I and heparin
lyase III (referred to as heparitinase treatment) (Seikagaku America) for 2 h
at 37
 
 
 
C, followed by addition of fresh enzyme for an additional 2 h com-
pletely removes endogenous HS. The unsaturated glucuronate remaining
on the core protein is recognized by mAb3G10 (Seikagaku America), al-
lowing examination of total HS distribution. Sections were incubated with
1:200 dilution of mAb3G10 in TBS containing 10% fetal calf serum for 1 h
at room temperature, followed by 1:300 Cy3-conjugated donkey anti–
mouse secondary antibody (Molecular Probes). Staining of sections with-
out prior enzyme treatment shows no 3G10 staining (unpublished data).
For analysis of FRAP binding to FGF immobilized on endogenous HS,
frozen sections were incubated with 30 nM native FGF-2 or FGF-4 for
1 h, then washed and incubated for an additional hour with 100 nM
FR1cAP or FR2cAP in TBS containing 10% fetal calf serum. Sections were
then treated with polyclonal rabbit anti-PLAP (Biomeda Corp.) for 30 min
followed by Alexa 546–conjugated goat anti–rabbit antibody (Molecular
Probes) for 30 min. Parallel sections were incubated with 1:10 fluores-
cein-conjugated PECAM-1 to identify capillaries. Parallel sections were
incubated with 1:300 smooth muscle actin monoclonal antibody, a gift of
Dr. Zsuzsa Fabry (University of Wisconsin–Madison, Madison, WI) to
identify large blood vessels.
 
Cell culture
 
MAECs were obtained from Dr. Robert Auerbach (University of Wiscon-
sin–Madison, Madison, WI) and cultured in DME, 10% fetal calf serum, 4
mM 
 
L
 
-glutamine, and 1% antibiotics (10,000 U penicillin/10 mg/ml strep-
tomycin). Generation of Raji-S1 Burkitt’s lymphoma cells has been de-
scribed previously (Lebakken and Rapraeger, 1996). Raji cells are negative
for proteoglycan expression and have been transfected with the cDNA for
mouse syndecan-1. Raji-S1 cells were cultured in RPMI 1640, 10% fetal
bovine serum, 4 mM glutamine, 1.5 mg/ml G418 sulfate, and 1% antibiot-
ics. FR1c11 and FR2c2 cells, BaF3 lymphoid cells expressing FR1c and
FR2c, respectively, were provided by Dr. David Ornitz. FR1c11 and
FR2c2 cells were cultured in RPMI 1640, 10% fetal calf serum, 10%
WEHI-3–conditioned medium, 4 mM 
 
L
 
-glutamine, 1% antibiotics, and
0.0035% 
 
 
 
-mercaptoethanol.
Morphology assay
MAECs were plated in DME containing 10% fetal calf serum at a concen-
tration of 4   10
3 cells/well in 8-well chamber slides (LAB-TEK). After
24 h, cells were washed with serum-free DME, and incubated at 37 C in
serum free DME with 10 nM FGF in the absence or presence of 10 nM por-
cine intestinal mucosa heparin (Sigma-Aldrich) for 72 h. Cells were then
fixed in 1% glutaraldehyde and photographed.
BaF3 proliferation assays
FR1c11 and FR2c2 cells were added to 96-well flat bottom plates (Fisher
Scientific) at a concentration of 10
5 cells/ml in IL-3–deficient media. FGF
(10 nM) was added and incubated at 37 C for 72 h in the presence or ab-
sence of 10 nM porcine intestinal mucosa heparin. After 72 h, CellTiter 96
AQueous One Solution reagent (Promega) was added to quantify relative
cell numbers using the manufacturer’s instructions.
For Raji-S1 cell–mediated survival/proliferation of the BaF3 cells, 2.5  
10
6 Raji-S1 cells/ml were allowed to adhere as a confluent monolayer to
96-well flat bottom plates for 2 h at 37 C in Hepes-buffered RPMI
[HbRPMI], 0.1% BSA, 4 mM L-glutamine, and 1% antibiotics. The mono-
layer was fixed for 1 h in 0.5% glutaraldehyde, followed by three washes
in PBS containing 0.2 M glycine, and incubated overnight in RPMI con-
taining 10% CS, 4mM L-glutamine, and 1% antibiotics. FR1c11 and FR2c2
cells were added to the Raji-S1 monolayer the next day in IL-3–deficient
media with or without FGF and treated as described above.856 The Journal of Cell Biology | Volume 155, Number 5, 2001
This work was supported by National Institutes of Health grant R01-
GM48850 to A.C. Rapraeger, an American Heart Association predoctoral
fellowship 0010170Z to B.L. Allen, and a grant from the Mitzutani Foun-
dation for Glycoscience.
Submitted: 31 May 2001
Revised: 27 September 2001
Accepted: 1 October 2001
References
Aird, W.C., J.M. Edelberg, H. Weiler-Guettler, W.W. Simmons, T.W. Smith, and
R.D. Rosenberg. 1997. Vascular bed–specific expression of an endothelial
cell gene is programmed by the tissue microenvironment. J. Cell Biol. 138:
1117–1124.
Andres, J.L., K. Stanley, S. Cheifetz, and J. Massague. 1989. Membrane-anchored
and soluble forms of betaglycan, a polymorphic proteoglycan that binds
transforming growth factor– . J. Cell Biol. 109:3137–3145.
Baird, A. 1994. Potential mechanisms regulating the extracellular activities of basic
fibroblast growth factor (FGF-2). Mol. Reprod. Dev. 39:43–48.
Bastaki, M., E.E. Nelli, P. Dell’Era, M. Rusnati, M.P. Molinari-Tosatti, S. Paro-
lini, R. Auerbach, L.P. Ruco, L. Possati, and M. Presta. 1997. Basic fibro-
blast growth factor-induced angiogenic phenotype in mouse endothelium. A
study of aortic and microvascular endothelial cell lines. Arterioscler. Thromb.
Vasc. Biol. 17:454–464.
Beckner, M.E. 1999. Factors promoting tumor angiogenesis. Cancer Invest. 17:
594–623.
Bennett, K.L., D.G. Jackson, J.C. Simon, E. Tanczos, R. Peach, B. Modrell, I. Sta-
menkovic, G. Plowman, and A. Aruffo. 1995. CD44 isoforms containing
exon V3 are responsible for the presentation of heparin-binding growth fac-
tor. J. Cell Biol. 128:687–698.
Bernfield, M., M. Gotte, P.W. Park, O. Reizes, M.L. Fitzgerald, J. Lincecum, and
M. Zako. 1999. Functions of cell surface heparan sulfate proteoglycans.
Annu. Rev. Biochem. 68:729–777.
Bullock, S.L., J.M. Fletcher, R.S. Beddington, and V.A. Wilson. 1998. Renal agen-
esis in mice homozygous for a gene trap mutation in the gene encoding
heparan sulfate 2-sulfotransferase. Genes Dev. 12:1894–1906.
Cancilla, B., M.D. Ford-Perriss, and J.F. Bertram. 1999. Expression and localiza-
tion of fibroblast growth factors and fibroblast growth factor receptors in the
developing rat kidney. Kidney Int. 56:2025–2039.
Chang, Z., K. Meyer, A.C. Rapraeger, and A. Friedl. 2000. Differential ability of
heparan sulfate proteoglycans to assemble the fibroblast growth factor recep-
tor complex in situ. FASEB J. 14:137–144.
Chellaiah, A., W. Yuan, M. Chellaiah, and D.M. Ornitz. 1999. Mapping ligand
binding domains in chimeric fibroblast growth factor receptor molecules.
Multiple regions determine ligand binding specificity. J. Biol. Chem. 274:
34785–34794.
Cohen, T., H. Gitay-Goren, R. Sharon, M. Shibuya, R. Halaban, B.Z. Levi, and
G. Neufeld. 1995. VEGF121, a vascular endothelial growth factor (VEGF)
isoform lacking heparin binding ability, requires cell-surface heparan sulfates
for efficient binding to the VEGF receptors of human melanoma cells. J.
Biol. Chem. 270:11322–11326.
Dell’Era, P., M. Belleri, H. Stabile, M.L. Massardi, D. Ribatti, and M. Presta.
2001. Paracrine and autocrine effects of fibroblast growth factor-4 in en-
dothelial cells. Oncogene. 20:2655–2663.
Delli-Bovi, P., A.M. Curatola, K.M. Newman, Y. Sato, D. Moscatelli, R.M.
Hewick, D.B. Rifkin, and C. Basilico. 1988. Processing, secretion, and bio-
logical properties of a novel growth factor of the fibroblast growth factor
family with oncogenic potential. Mol. Cell. Biol. 8:2933–2941.
Faham, S., R.J. Linhardt, and D.C. Rees. 1998. Diversity does make a difference:
fibroblast growth factor-heparin interactions. Curr. Opin. Struct. Biol.
8:578–586.
Filla, M.S., P. Dam, and A.C. Rapraeger. 1998. The cell surface proteoglycan syn-
decan-1 mediates fibroblast growth factor-2 binding and activity. J. Cell.
Physiol. 174:310–321.
Filmus, J. 2001. Glypicans in growth control and cancer. Glycobiology. 11:19R–
23R.
Flaumenhaft, R., D. Moscatelli, and D.B. Rifkin. 1990. Heparin and heparan sul-
fate increase the radius of diffusion and action of basic fibroblast growth fac-
tor. J. Cell Biol. 111:1651–1659.
Friedl, A., Z. Chang, A. Tierney, and A.C. Rapraeger. 1997. Differential binding
of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate:
comparison of normal and abnormal human tissues. Am. J. Pathol. 150:
1443–1455.
Gengrinovitch, S., B. Berman, G. David, L. Witte, G. Neufeld, and D. Ron. 1999.
Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular
chaperone for VEGF165. J. Biol. Chem. 274:10816–10822.
Gospodarowicz, D., and J. Cheng. 1986. Heparin protects basic and acidic FGF
from inactivation. J. Cell Physiol. 128:475–484.
Guimond, S.E., and J.E. Turnbull. 1999. Fibroblast growth factor receptor signal-
ling is dictated by specific heparan sulphate saccharides. Curr. Biol. 9:1343–
1346.
Guimond, S., M. Maccarana, B.B. Olwin, U. Lindahl, and A.C. Rapraeger. 1993.
Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Dis-
tinct requirements for FGF-1, FGF-2, and FGF-4. J. Biol. Chem. 268:
23906–23914.
Habuchi, H., M. Kobayashi, and K. Kimata. 1998. Molecular characterization and
expression of heparan-sulfate 6-sulfotransferase. Complete cDNA cloning in
human and partial cloning in Chinese hamster ovary cells. J. Biol. Chem.
273:9208–9213.
Iozzo, R.V. 1998. Matrix proteoglycans: from molecular design to cellular func-
tion. Annu. Rev. Biochem. 67:609–652.
Jackson, D.G., J.I. Bell, R. Dickinson, J. Timans, J. Shields, and N. Whittle. 1995.
Proteoglycan forms of the lymphocyte homing receptor CD44 are alterna-
tively spliced variants containing the v3 exon. J. Cell Biol. 128:673–685.
Johnson, D.E., and L.T. Williams. 1993. Structural and functional diversity in the
FGF receptor multigene family. Adv. Cancer Res. 60:1–41.
Kan, M., F. Wang, J. Xu, J.W. Crabb, J. Hou, and W.L. McKeehan. 1993. An es-
sential heparin-binding domain in the fibroblast growth factor receptor ki-
nase. Science. 259:1918–1921.
Kleeff, J., T. Ishiwata, A. Kumbasar, H. Friess, M.W. Buchler, A.D. Lander, and
M. Korc. 1998. The cell-surface heparan sulfate proteoglycan glypican-1
regulates growth factor action in pancreatic carcinoma cells and is overex-
pressed in human pancreatic cancer. J. Clin. Invest. 102:1662–1673.
Kobayashi, M., H. Habuchi, M. Yoneda, O. Habuchi, and K. Kimata. 1997. Mo-
lecular cloning and expression of Chinese hamster ovary cell heparan-sulfate
2-sulfotransferase. J. Biol. Chem. 272:13980–13985.
Lebakken, C.S., and A.C. Rapraeger. 1996. Syndecan-1 mediates cell spreading in
transfected human lymphoblastoid (Raji) cells. J. Cell Biol. 132:1209–1221.
Li, J., A. Hagner-McWhirter, L. Kjellen, J. Palgi, M. Jalkanen, and U. Lindahl.
1997. Biosynthesis of heparin/heparan sulfate. cDNA cloning and expres-
sion of D-glucuronyl C5-epimerase from bovine lung. J. Biol. Chem. 272:
28158–28163.
Lin, X., E.M. Buff, N. Perrimon, and A.M. Michelson. 1999. Heparan sulfate pro-
teoglycans are essential for FGF receptor signaling during Drosophila embry-
onic development. Development. 126:3715–3723.
Lindahl, U. 1997. Heparan sulfate: a polyanion with multiple messages. Pure Appl.
Chem. 69:1897–1902.
Lindahl, U., M. Kusche-Gullberg, and L. Kjellen. 1998. Regulated diversity of
heparan sulfate. J. Biol. Chem. 273:24979–24982.
Lough, J., M. Barron, M. Brogley, Y. Sugi, D.L. Bolender, and X. Zhu. 1996.
Combined BMP-2 and FGF-4, but neither factor alone, induces cardiogene-
sis in non-precardiac embryonic mesoderm. Dev. Biol. 178:198–202.
Lyon, M., J.A. Deakin, and J.T. Gallagher. 1994. Liver heparan sulfate structure. A
novel molecular design. J. Biol. Chem. 269:11208–11215.
Maccarana, M., B. Casu, and U. Lindahl. 1993. Minimal sequence in heparin/
heparan sulfate required for binding of basic fibroblast growth factor. J. Biol.
Chem. 268:23898–23905.
Martin, G.R. 1998. The roles of FGFs in the early development of vertebrate
limbs. Genes Dev. 12:1571–1586.
Miki, T., D.P. Bottaro, T.P. Fleming, C.L. Smith, W.H. Burgess, A.M. Chan, and
S.A. Aaronson. 1992. Determination of ligand-binding specificity by alter-
native splicing: two distinct growth factor receptors encoded by a single
gene. Proc. Natl. Acad. Sci. USA. 89:246–250.
Miyagawa, K., H. Sakamoto, T. Yoshida, Y. Yamashita, Y. Mitsui, M. Furusawa, S.
Maeda, F. Takaku, T. Sugimura, and M. Terada. 1988. hst-1 transforming
protein: expression in silkworm cells and characterization as a novel heparin-
binding growth factor. Oncogene. 3:383–389.
Noonan, D.M., A. Fulle, P. Valente, S. Cai, E. Horigan, M. Sasaki, Y. Yamada,
and J.R. Hassell. 1991. The complete sequence of perlecan, a basement
membrane heparan sulfate proteoglycan, reveals extensive similarity with
laminin A chain, low density lipoprotein-receptor, and the neural cell adhe-
sion molecule. J. Biol. Chem. 266:22939–22947.
Ornitz, D.M., A. Yayon, J.G. Flanagan, C.M. Svahn, E. Levi, and P. Leder. 1992.HS regulates FGF and FGF receptor recognition | Allen et al. 857
Heparin is required for cell-free binding of basic fibroblast growth factor to a
soluble receptor and for mitogenesis in whole cells. Mol.Cell Biol. 12:240–
247.
Ornitz, D.M., J. Xu, J.S. Colvin, D.G. McEwen, C.A. MacArthur, F. Coulier, G.
Gao, and M. Goldfarb. 1996. Receptor specificity of the fibroblast growth
factor family. J. Biol. Chem. 271:15292–15297.
Paria, B.C., K. Elenius, M. Klagsbrun, and S.K. Dey. 1999. Heparin-binding
EGF-like growth factor interacts with mouse blastocysts independently of
ErbB1: a possible role for heparan sulfate proteoglycans and ErbB4 in blasto-
cyst implantation. Development. 126:1997–2005.
Park, P.W., O. Reizes, and M. Bernfield. 2000. Cell surface heparan sulfate pro-
teoglycans: selective regulators of ligand-receptor encounters. J. Biol. Chem.
275:29923–29926.
Pellegrini, L., D.F. Burke, F. von Delft, B. Mulloy, and T.L. Blundell. 2000. Crys-
tal structure of fibroblast growth factor receptor ectodomain bound to ligand
and heparin. Nature. 407:1029–1034.
Pye, D.A., R.R. Vives, J.E. Turnbull, P. Hyde, and J.T. Gallagher. 1998. Heparan
sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibro-
blast growth factor mitogenic activity. J. Biol. Chem. 273:22936–22942.
Rapraeger, A.C. 2001. Heparan sulfate-growth factor interactions. In Methods in
Cell Adhesion. J.C. Adams, editor. Academic Press, New York. In press.
Rapraeger, A.C., A. Krufka, and B.B. Olwin. 1991. Requirement of heparan sulfate
for bFGF-mediated fibroblast growth and myoblast differentiation. Science.
252:1705–1708.
Sakata, H., S.J. Stahl, W.G. Taylor, J.M. Rosenberg, K. Sakaguchi, P.T. Wing-
field, and J.S. Rubin. 1997. Heparin binding and oligomerization of hepato-
cyte growth factor/scatter factor isoforms. Heparan sulfate glycosamino-
glycan requirement for Met binding and signaling. J. Biol. Chem. 272:
9457–9463.
Schlessinger, J., A.N. Plotnikov, O.A. Ibrahimi, A.V. Eliseenkova, B.K. Yeh, A.
Yayon, R.J. Linhardt, and M. Mohammadi. 2000. Crystal structure of a ter-
nary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR
binding and dimerization. Mol. Cell. 6:743–750.
Sergeant, N., M. Lyon, P.S. Rudland, D.G. Fernig, and M. Delehedde. 2000.
Stimulation of DNA synthesis and cell proliferation of human mammary
myoepithelial-like cells by hepatocyte growth factor/scatter factor depends
on heparan sulfate proteoglycans and sustained phosphorylation of mitogen-
activated protein kinases p42/44. J. Biol. Chem. 275:17094–17099.
Shworak, N.W., J. Liu, L.M. Fritze, J.J. Schwartz, L. Zhang, D. Logeart, and R.D.
Rosenberg. 1997. Molecular cloning and expression of mouse and human
cDNAs encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase.  J.
Biol. Chem. 272:28008–28019.
Slavin, J. 1995. Fibroblast growth factors: at the heart of angiogenesis. Cell. Biol.
Int. 19:431–444.
Sugi, Y., J. Sasse, M. Barron, and J. Lough. 1995. Developmental expression of fi-
broblast growth factor receptor-1 (cek-1; flg) during heart development.
Dev. Dyn. 202:115–125.
Szebenyi, G., and J.F. Fallon. 1999. Fibroblast growth factors as multifunctional
signaling factors. Int. Rev. Cytol. 185:45–106.
The, I., Y. Bellaiche, and N. Perrimon. 1999. Hedgehog movement is regulated
through tout velu-dependent synthesis of a heparan sulfate proteoglycan.
Mol. Cell. 4:633–639.
Tsuda, M., K. Kamimura, H. Nakato, M. Archer, W. Staatz, B. Fox, M. Hum-
phrey, S. Olson, T. Futch, V. Kaluza, et al. 1999. The cell-surface proteogly-
can Dally regulates Wingless signalling in Drosophila. Nature. 400:276–280.
Turnbull, J.E., D.G. Fernig, Y. Ke, M.C. Wilkinson, and J.T. Gallagher. 1992.
Identification of the basic fibroblast growth factor binding sequence in fibro-
blast heparan sulfate. J. Biol. Chem. 267:10337–10341.
van Kuppevelt, T.H., M.A. Dennissen, W.J. van Venrooij, R.M. Hoet, and J.H.
Veerkamp. 1998. Generation and application of type-specific anti-heparan
sulfate antibodies using phage display technology. Further evidence for
heparan sulfate heterogeneity in the kidney. J. Biol. Chem. 273:12960–
12966.
Venkataraman, G., R. Raman, V. Sasisekharan, and R. Sasisekharan. 1999. Molec-
ular characteristics of fibroblast growth factor-fibroblast growth factor recep-
tor-heparin-like glycosaminoglycan complex. Proc. Natl. Acad. Sci. USA. 96:
3658–3663.
Wei, Z., S.J. Swiedler, M. Ishihara, A. Orellana, and C.B. Hirschberg. 1993. A sin-
gle protein catalyzes both N-deacetylation and N-sulfation during the bio-
synthesis of heparan sulfate. Proc. Natl. Acad. Sci. USA. 90:3885–3888.
Werner, S., D.S. Duan, C. de Vries, K.G. Peters, D.E. Johnson, and L.T. Wil-
liams. 1992. Differential splicing in the extracellular region of fibroblast
growth factor receptor 1 generates receptor variants with different ligand-
binding specificities. Mol. Cell. Biol. 12:82–88.
Yayon, A., M. Klagsbrun, J.D. Esko, P. Leder, and D.M. Ornitz. 1991. Cell sur-
face, heparin-like molecules are required for binding of basic fibroblast
growth factor to its high affinity receptor. Cell. 64:841–848.
Yoshida, T., K. Ishimaru, H. Sakamoto, J. Yokota, S. Hirohashi, K. Igarashi, K.
Sudo, and M. Terada. 1994. Angiogenic activity of the recombinant hst-1
protein. Cancer Lett. 83:261–268.
Zhu, X., J. Sasse, D. McAllister, and J. Lough. 1996. Evidence that fibroblast
growth factors 1 and 4 participate in regulation of cardiogenesis. Dev. Dyn.
207:429–438.
Zimmermann, P., and G. David. 1999. The syndecans, tuners of transmembrane
signaling. FASEB J. 13:S91–S100.